相关实验视频

Updated: Jun 13, 2025

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

在C型肝炎感染者,治愈者和从未感染的对照者中比较不良结果的风险

Varun Saxena^1,2, Weilu Wu³, Sreepriya Balasubramanian¹

¹Gastroenterology and Hepatology, Kaiser Permanente, Oakland, California.

Gastro hep advances

|September 16, 2024

概括

治疗C型肝炎病毒 (HCV) 显著减少了不良结果,但与未感染个体相比,并不总能使风险正常化. 在HCV治愈后的低风险组可能会避免持续的专科护理.

科学领域:

肝病学肝病学是一种肝病学.
传染性疾病传染性疾病
公共卫生公共卫生

背景情况:

型肝炎病毒 (HCV) 治愈与减少不良健康结果有关.
然而,在治愈的HCV患者和从未感染过的人之间,没有直接比较结果.
这种数据缺口影响了关于治疗后专科后续治疗的决策.

研究的目的:

为了比较从未感染过HCV的人与从未感染过HCV的人之间的健康状况不佳的风险.
确定治愈的HCV患者的低风险子组,这些患者可能不需要持续的专业护理.
根据临床指导方针,制定治疗后的后续战略.

主要方法:

一项回顾性队列研究使用了2002-2019年的数据进行.
分析了三个队列:慢性HCV,HCV治愈和匹配的HCV阴性对照.
结局包括肝硬化,不补偿性肝硬化,肝细胞癌 (HCC) 和全因死亡率.

主要成果:

与慢性HCV相比,HCV治愈显著降低了肝硬化,5年累计发病率,失补偿性肝硬化,HCC和全因死亡率.
然而,在HCV治愈的个体中,这些结果的风险在数量上仍然高于从未感染过的对照组.
一个低风险的HCV治愈个体的子组显示出数量上与对照组相似的结果.

结论:

虽然治疗HCV提供了巨大的好处,但它可能无法完全恢复一般人群的风险.
分层治愈的个体来确定一个低风险组是可行的.
这种分层可以使护理减缓,包括从专科诊所出院和停止对特定患者的HCC监测.

关键词:

肝硬化是肝硬化的一种疾病.脱补偿性肝硬化治疗C型肝炎治愈C型肝炎肝细胞癌肝细胞癌包容包容包容包容包容人口管理的人口管理.

更多相关视频

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

相关概念视频

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...